Home /

Latest news

September 10, 2026

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable November 16, 2026, to stockholders of record at the...

September 10, 2026

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

Menstrual migraine is a recurrent, debilitating migraine pattern, with attacks occurring around or during the menstrual period, a predictable time of increased biological vulnerability2,4...

September 03, 2026

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival,...

AbbVie on

Looking for more news from AbbVie? Follow us on social media.

Press Kits

Our press kits are designed to provide journalists with a broad range of background information on our company.

Image library

Our media library provides you with our official AbbVie media including our logo, building and leaders.

Stay up to date on recent news, articles, and more.

News

Month Year

Get News Alerts by Email

August 11, 2005

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2005 Financial Results; Company Provides Business Update
July 26, 2005

ImmunoGen, Inc. Announces Genentech Has Licensed Rights to Use ImmunoGen's TAP Technology with Therapeutic Antibodies to an Additional Target
June 24, 2005

ImmunoGen, Inc. Announces Initiation of Clinical Testing of its HuC242-DM4 Anticancer Compound; Company's Second Wholly-Owned TAP Compound Advances into Clinical Testing
June 09, 2005

ImmunoGen, Inc. Announces Addition of Nicole Onetto, MD, to the Board of Directors
May 17, 2005

ImmunoGen, Inc. Reports Initial Phase II Findings with its HuN901-DM1 Anticancer Compound in the Treatment of Small-Cell Lung Cancer; Company's Lead TAP Compound Demonstrates Objective Evidence of Anticancer Activity
May 09, 2005

ImmunoGen, Inc. Announces Appointment of Daniel M. Junius as Chief Financial Officer
May 05, 2005

ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2005 Financial Results
May 03, 2005

ImmunoGen, Inc. Announces Genentech's Renewal of Technology Access Agreement
April 28, 2005

ImmunoGen, Inc. Announces Genentech Has Licensed Rights to Use ImmunoGen's TAP Technology with Therapeutic Antibodies to a Second Target
April 19, 2005

ImmunoGen, Inc. Announces Data Reported at AACR on AVE9633 Anticancer Compound
April 17, 2005

ImmunoGen, Inc. Reports Data at AACR on the Company's HuC242-DM4 Anticancer Compound
March 31, 2005

ImmunoGen, Inc. Files IND for its HuC242-DM4 Targeted Anticancer Compound
March 17, 2005

ImmunoGen Announces Achievement of Milestone in Collaboration with Sanofi-Aventis
February 09, 2005

ImmunoGen, Inc. Provides Update on Collaboration with Boehringer Ingelheim
February 03, 2005

ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2005 Financial Results; Company Provides Business Update
January 07, 2005

ImmunoGen, Inc. Announces Departure of Chief Financial Officer
December 28, 2004

ImmunoGen, Inc. Announces that Centocor Has Licensed Certain Rights to ImmunoGen's Tumor-Activated Prodrug Technology
November 04, 2004

ImmunoGen, Inc. Reports First Quarter Fiscal Year 2005 Financial Results; Company Provides Business Update
October 25, 2004

ImmunoGen, Inc. Appoints Christopher U. Missling as Chief Financial Officer
October 06, 2004

Biogen Idec and ImmunoGen, Inc. to Collaborate on Development of Novel Anticancer Compound
August 12, 2004

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2004 Financial Results; Revenue From Partners Increased Substantially Over 2003 Levels
July 08, 2004

ImmunoGen, Inc. Announces Publication of Preclinical Data on the Anticancer Activity of huN901-DM1 in Multiple Myeloma
July 06, 2004

ImmunoGen, Inc. Appoints Dr. Robert J. Fram as Vice President, Clinical Development
June 22, 2004

ImmunoGen, Inc. Announces Addition to its Board of Directors
May 27, 2004

ImmunoGen, Inc. Announces Placement of Common Stock by Selling Stockholder

Show per page

Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more

Sustainability

Our commitment to science is a commitment to better our society. Read our 2025 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more

Annual report

See our latest 2025 Annual Report on Form 10-K. Learn more

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?